The goal of this clinical trial is to evaluate the efficacy and safety of 25-gauge pars plana vitrectomy combined with intravitreal dexamethasone implant for the treatment of idiopathic epiretinal membrane with cystoid macular oedema. The main questions it aims to answer are: * mean changes in best corrected visual acuity and central macular thickness from baseline to post-operative 24 weeks * mean change in proportion of cystoid macular oedema area from baseline to post-operative 24 weeks * intraocular pressure throughout postoperative 24 weeks * concentrations of inflammatory factors in vitreous samples Participants will undergo a standard three-port 25-gauge pars plana vitrectomy and epiretinal membrane peeling combined with phacoemulsification, aspiration, and intraocular lens implantation. The dexamethasone implant will be injected into the vitreous cavity at the end of the operation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
Shanghai Eye Disease Prevention & Treatment Center
Shanghai, Shanghai Municipality, China
improvement of visual acuity
mean change in best corrected visual acuity
Time frame: from baseline to postoperative 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.